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Abstract 
Welfare regulation in the European Union (EU) continues to crawl forward despite salient conflicts 
of interests. This paper addresses the fundamental puzzle of how regulatory competences may 
expand into the core of the welfare state and how conflicts are, eventually, managed in such 
processes. It analyses the EU cross-border provision of healthcare services. It is argued that the 
interplay between the Commission and the Court constitutes a powerful dynamic in generating new 
regulatory activities and in finding ways to set conflicts aside. The Commission draws on 
formulations offered by the Court in finding ways to manage conflict, for example by requiring 
‘proportionate’ national policies which establish that national obstacles to free movement 
principles are ‘objectively necessary’. The paper concludes that law and evidence serve as powerful 
resources for the Commission in managing conflict.  
 
Introduction  
Welfare regulation in the European Union (EU) may lack a formal political mandate, but 
paradoxically continues to crawl forward. It moves forward as a result of free movement principles, 
developed through the non-political powers of European Court of Justice (ECJ) and the 
Commission. Inbuilt joint decision traps make it increasingly difficult to reverse the integration 
undertaken (Scharpf 2006, 2007). This paper analyses how EU healthcare integration is moving 
beyond the legal realm in which it has so far been advanced into a proposed administrative space of 
regulation. It thus examines how judicial interpretations feed into regulatory action, and how the 
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 2 
Commission reasons regulatory actions and aims to tackle conflicts through the voice of law and 
evidence-based politics. The Commission-Court tandem is under examination, as well as the policy-
shaping role of judicial integration, monitored by the Commission (Schmidt 2000; Schmidt 2004).   
  
Article 49 of the Treaty envisages that there should be freedom to consume services throughout the 
single market. However, directives to develop the application of this Article in the area of social 
welfare have been blocked. This paper shows how social regulation in the EU has nonetheless 
expanded, both in substantive reach and effective impact on national welfare systems. Health care is 
a striking example of how social regulation has progressed beyond the classic ‘regulatory function’ 
into the ‘redistribution function’ as defined by Majone (Majone 1994; 1996). The development of 
an EU regulatory state in health care comes up against intense conflicts of interests. While 
competition between service providers across national boundaries can be justified as increasing 
allocative efficiency in the internal market for services, competition also has redistributive 
consequences. Traditionally healthcare has been allocated within the national territory to those 
residing there. If patients can travel abroad and then seek reimbursement for the cost of health 
services consumed elsewhere, domestic practices governing the allocation of these services may be 
challenged. Of particular political salience is the way that the institutionalisation of cross-border 
service provision can make it possible for mobile patients to queue-jump and access treatment more 
quickly, as well as possibly obtaining treatments that are not available domestically. 
 
The second section of this paper shows how the European Court of Justice (ECJ) has played a 
particularly active role in this area. In its interpretations on free movement of healthcare services 
which will be analysed below, the Court has directly raised redistributive questions. What is a 
reasonable time for a patient to wait for a treatment when it more efficiently can be provided in the 
next-door member state? And on which grounds can a member state’s healthcare insurance system 
deny a patient access to a treatment available in another EU member state?  It is shown that the 
Court’s responses to these questions call for a regulatory framework, proposing as they do that 
decisions about prior authorisation for patients seeking treatment abroad should be based on 
‘objective, nondiscriminatory criteria’. Such review of national measures is conducted against the 
principle of proportionality, which implies that national authorities are obliged to prove that policies 
are ‘suitable’ and ‘necessary’ if they constitute obstacles to the free movement of services. 
Furthermore, the regulatory framework proposes that available treatments should be determined by 
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‘international medical science’, and that waiting lists may be jumped when there is ‘undue delay’, 
and so on. All these formulations suppose that an international community of experts would be able 
to reach agreement on how these terms should be applied. The Court can be seen as formulating the 
issues presented in the cases before it in ways which are susceptible to solution through regulatory 
techniques, particularly through the references to expertise and the call for formalisation and 
transparency.   
 
The third section shows how the Commission has taken up these formulations in its proposal for a 
Directive on the cross-border provision of health care.  The Commission refers to the legal 
reasoning of the Court and finds back-up in the authoritative ‘voice of law’ when framing a policy 
problem to be undertaken at Community level. It thus translates the policy problem identified into a 
‘regulatory need’. Legal reasoning, which points out the relevant issue at stake and the relevant 
rules to be discussed and applied, frames the issues raised in individual cases in more general 
regulatory manner, identifying regulatory activities which need to be undertaken at Community 
level. Such line of case-law constitutes a strong platform upon which the Commission can argue the 
need to clarify and codify through legislation. The individual conflicts and issues are taken beyond 
the Court’s domain and into the administrative domain of the Commission. In this way, Court 
rulings move from ex-post interpretation into ex-ante validation of new regulatory activities. The 
link between judicial decision-making and the regulatory proposals is strong. For example, the 
Commission proposes to introduce an administrative review of proportionality which clearly 
resembles the Court’s principle. Prior authorisation is only justifiable if national authorities can 
evidence that such policy is ‘suitable’ and ‘necessary’.    
 
The obvious question – to which there is as yet no answer – is whether the Commission’s proposal 
will come to constitute an example of conflict management through regulation. In other words, will 
the member states put aside their objections, strongly expressed in the course of negotiations over 
the Services Directive, to the encroachment of Community regulation on this area of social welfare? 
The EU has already entered the area of healthcare regulation through several routes, including free 
movement of health professionals and patients, the purchase of pharmaceuticals in other member 
states, coordination of social security and more recently the open method of coordination (Greer 
2006; Hervey 2008; Hervey & McHale 2004; Kostera 2008; Lamping 2005; Mossialos et. al. 2002; 
Permanand & Mossialos 2005; Palm et al. 2000; Martinsen & Vrangbæk 2008). For the reasons 
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outlined above, the cross-border provision of services through patient mobility has redistributive 
consequences that are politically salient, suggesting that regulation is more likely to be blocked. The 
argument of this paper is that, whatever the fate of this particular proposal, the Court’s framing of 
the issues has created a significant impetus in this area of social regulation. 
 
2. Regulating Health Care in the European Union  
Until 1998, Regulation 1408/71
1
 was the main regulatory source for cross-border treatment in the 
EU. By means of the 1408/71 coordination scheme, patient mobility in the European Union was 
primarily based on precisely established balances between some access to the healthcare supplies of 
other member states through the regulatory system of 1408, but firmly controlled nationally through 
the governing principle of ‘prior authorisation’. ‘Prior authorisation’ had for long constituted the 
effective means of national control. The principle lies down that if a patient requests to receive a 
publicly financed healthcare treatment in another member state, it has to be authorised beforehand 
by the competent healthcare institution. From 1998 onwards ECJ judgements seriously came to 
upset the established status quo between Community law and national legislation.  
 
2.1 How judicial interpretations led the way  
In a series of judgements, the European Court of Justice questioned the justification of ‘prior 
authorisation’ and gradually established that the principles of the internal market – and especially 
Article 49 of the Treaty - also applied to national health policies. The line of case-law that the ECJ 
has produced since 1998 is a remarkable example of the Court’s ability to progress European 
integration into the core of the welfare state – and thus redistributive politics. In this way, judicial 
interpretations of the scope and purpose of the Treaty prepare the terrain for further regulatory 
action. We then find that Court decisions – and not political aims or visions – indirectly set the 
agenda for new regulatory competences of the Community. Court decisions constitute authoritative 
reasoning which is reflected in the Commission’s argumentative logic and formulation of proposals. 
In this way, the voice of law becomes ‘the force of the better argument’, through which the 
                                                 
1
 Regulation (EEC) No. 1408/71 of the Council of 14 June 1971 on the application of social security schemes to 
employed persons, to self-employed persons and to members of their families moving within the Community. The 
regulation has recently been substantially reformed with the adoption of Regulation 883/2004. Although adopted 29
th
 
April 2004, Regulation 883/2004 has not yet entered into force as it awaits the adoption of the implementing regulation, 
which is currently under negotiation.   
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regulatory need and the proposed solution are developed. The ‘principle of proportionality’ 
constitutes a central point of reasoning in the process furthering Community healthcare competence, 
whereby prior authorisation is evaluated against what is proportional.  This has proved to be a 
powerful principle, since it gives grounds for the judiciary to determine whether the prior 
authorisation is ‘suitable’ and ‘necessary’. The same logic of ‘putting to test’ whether a public 
policy measure is suitable and necessary is subsequently taken up by the evidence-based policy of 
the Commission, as will be demonstrated below.      
 
The judicial background for the regulatory need unfolds in detailed manner through a decade of 
step-wise interpretations. In the introductory judgements of Decker and Kohll, the Court laid down 
that healthcare was a service within the meaning of the Treaty and therefore in principle subject to 
the freedom to provide services across borders.
2
 The requirement of prior authorisation was found 
to be a barrier to exercising this freedom, which, nevertheless, could be justified under certain 
circumstances. The first as well as the subsequent Court decisions in this way put forward a delicate 
balance of, on the one hand, cross-border freedom to provide services, and, on the other hand, 
grounds upon which to justify deviations from the  application of this principle to healthcare. As an 
accepted departure from the general rule of free movement, the  judgements acknowledge the risk 
of seriously undermining the financial balance of the social security system, the need to maintain a 
balanced medical and hospital service open to all and the need to plan nationally the capacities of 
the healthcare system.
3
 In this way, the Court entered the significant conflict between the market 
freedoms of the European Union and the redistributive competences of the member states.     
 
The immediate impact of the 1998 judgements was modest in that they considered only a limited 
scope of goods and services outside the hospital sector, namely a pair of spectacles and dental 
treatment. Furthermore the initial cases concerned the reimbursement-based Luxembourg healthcare 
system. Although at first severely upset, politicians found themselves reassured that the impact was 
                                                 
2
 In the cases C-120/95, Decker, [1998], ECR I-1831 and C-158/96, Kohll, [1998], ECR I-1931.   
 
3
 See Kohll, para 41, 50, 51; Smits and Peerbooms, para 72, 73, 74; Müller-Fauré and Van Riet, para 67, 73; Watts, para 
103-105.   
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limited to rather specific goods and services and to particular healthcare systems as the Luxembourg 
one.
4
    
 
Nevertheless in subsequent rulings, the ECJ extended its interpretation across the full range of EU 
healthcare systems. The Geraets-Smits and Peerbooms judgement of 2001
5
 repeated - this time with 
regard to the Dutch ‘benefit in kind’ health insurance system - that prior authorisation constitutes a 
barrier to the free movement of services. Such a barrier may, however, be justified provided that 1) 
the decision on whether or not to grant treatment abroad is based on “international medical science” 
and 2) an equivalent course of treatment can be provided in the competent member state without 
“undue delay” taking into consideration the medical condition of the patient, broadly defined. In the 
case of Peerbooms, the Court considered the right of Mr. Peerbooms to access a treatment which 
was not provided as part of the national health care package, but considered experimental by the 
Dutch system. The Court ruled that the decision on what is a ‘normal’ or a standard treatment has to 
be based on international medical science and not on national considerations alone. In this way, the 
Court envisages that citizens may access other treatments than those allocated in the national 
package. In addition, the Smits and Peerbooms cases present another regulatory question: what is a 
reasonable waiting time for healthcare treatment? The Court lay down that the patient shall not 
suffer ‘undue delay’; otherwise s/he is entitled to seek treatment across borders. Waiting lists as 
allocative mechanism in national health care organisation are thereby restricted by Community law.  
 
In the Smits and Peerbooms cases and the subsequent ones, the Court assessed prior authorisation 
against the principle of proportionality.
6
 One could argue that in the concrete case, as well as in the 
cases below, prior authorisation fails the test of proportionality. The national measure to control 
                                                 
4
 It can thus be argued that the majority of member states at first found themselves shielded from internal market 
pressures by the features of the national health care model. EU healthcare families can roughly be divided into two 
models/basic institutional design (Ferrera 2005, p. 124). One model is organised as a National Health Service, covering 
the residing population universally and offering healthcare as benefits in kind. The other model is organised as a social 
insurance/Bismarkian model, structured on performance or income reflecting criteria. The social insurance model can 
further be divided into two sub-categories. One which supply healthcare as benefit in kind, and another based on 
reimbursement, i.e. where the patient is subsequently reimbursed for healthcare cost by her/his healthcare insurance 
fund. For a division of healthcare supply across the EU member states (EU-25), see Martinsen 2007, pp. 23-24.  
    
5
 Case C-157/99, Geraets-Smits and Peerbooms, [2001], ECR I-5473.   
 
6
 For the proportionality principle, see paras. 75 & 82 of the Smits-Peerbooms cases; paras 68 & 83 of the Müller-Fauré 
cases and paras 106 and 114 of the Watts case. .  
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healthcare consumption is not precluded as a matter of principle – there may be reasons for it – but 
its justifiability and objective necessity does not stand the test conducted by the Court.    
 
In the case of Smits and Peerbooms, the Court further restricted national authorities’  discretion in 
granting prior authorisation by emphasising that it can only be a justified barrier to the principle of 
free provision of services if it is based on ‘objective, non-discriminatory criteria known in advance’ 
so that national authorities cannot control the procedure arbitrarily. Requests for authorisation must 
furthermore be dealt with within a reasonable time, and refusals to grant authorisation must be open 
to appeal (para. 90, C-157/99). In this way, the Court established that decisions on authorisation 
must be reasoned, reviewable and issued according to an acceptable administrative practice. They 
must be reviewed against the proportionate doctrine. By its emphasis on objectivity, explicit and 
assessable criteria and non-discrimination the Court furthermore presented its reasoning through 
regulatory formulations, later to be taken up by the Commission.   
 
A further significant step on the construction of EU healthcare regulation took place two years later 
with the case of Müller-Fauré & Van Riet
7
. In this case, the Court issued yet another expansive 
interpretation by introducing a distinction between hospital and non-hospital care. In the case of 
hospital care, the Court restated its view that the requirement for prior authorisation is justified on 
condition that it is exercised proportionately and that the national authority has no scope for acting 
in an arbitrary manner. The matter was, however, quite different for non-hospital care. The Court 
ruled that national authorisation constitutes a barrier to the freedom to provide services for non-
hospital care, and that persuasive justification for maintaining such a barrier had not been brought 
before the Court. Again the concrete cases failed the proportionality test.  
 
The Court proceeded further in the case of Watts
8
 where it ruled against the UK. The Watts case 
considered for the first time, the implications of the logic of the internal market for member states 
that generally combine the provision and financing of healthcare, such as the UK, Ireland, the 
Scandinavian countries and the Southern Member States, i.e. National Health Services organised as 
benefits in kind. In relation to the earlier line of case law, member states with National Health 
                                                 
7
 Case C-385/99, Müller-Fauré and Van Riet, [2003], ECR I-4509.    
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Service systems had argued that such organisation in general shielded them from openness to the 
cross-border provision of services. Mrs. Watts had, however, paid for the treatment in the first 
place, which made it possible for the Court to consider the case from the parameters of the Treaty’s 
article 49.  
 
The Watts case meant that the rights of the European citizen, here acting as a patient, were brought 
into sharper focus. The matter concerned waiting lists as allocative means, and their justifiability. In 
this case, the Court entered further into the question of what constitutes ‘undue delay’, and set out a 
reviewable criterion for determining whether a period of waiting is acceptable in the context of EC 
law. The waiting time must not: 
 
“exceed the period which is acceptable on the basis of an objective medical assessment of the clinical needs of the 
person concerned in the light of all of the factors characterising his medical condition at the time when the request 
for authorisation is made or renewed, as the case may be” (paragraph 79 of the judgement, emphasis added). 
 
Furthermore, the decision as to whether the patient faces undue delay in accessing services must be 
based on:  
“an objective medical assessment of the patient’s medical condition, the history and probable course of his illness, 
the degree of pain he is in and/or the nature of his disability at the time when the request for authorisation was 
made or renewed” (paragraph 119 of the judgement, emphasis added). 
 
Having enhanced the rights of the European patient by setting limits to the time period and the 
grounds on which the exercise of supranational rights can be put on hold, the Court went on to 
specify the institutional structures that member states must provide to protect those rights. The 
Court repeated the conclusions from Geraets-Smits and Peerbooms as well as Müller-Fauré and 
van Riet, and stated that the prior authorisation procedures in member states cannot be 
discretionary, but must be based on objective, non-discriminatory criteria and allow for decisions on 
authorisation to be challenged in judicial or quasi-judicial proceedings (paragraphs. 115-116). Only 
when national administrations live up to these procedural requirements may their measures be 
found proportionate. Furthermore,  
 
“To that end, refusals to grant authorisation, or the advice on which such refusals may be based, must refer to the 
specific provisions on which they are based and be properly reasoned in accordance with them. Likewise, courts 
or tribunals hearing actions against such refusals must be able, if they consider it necessary for the purpose of 
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carrying out the review which it is incumbent on them to make, to seek the advice of wholly objective and 
impartial independent experts” (paragraph 117 of the judgement, emphasis added).   
 
From Decker/Kohll via Smits/Peerbooms to Müller-Fauré and Watts, it is clear that legal decisions 
have been pivotal to the integration of healthcare. Within a time span of less than a decade, national 
health policies have been taken far further into the internal market than politicians ever intended, or 
could have predicted. That EC law applies regardless of the organising characteristics of national 
healthcare systems when the conditions of the Treaty’s article 49 are met.  
 
Furthermore, the line of cases on patient mobility is rich in regulatory language, which however has 
redistributive impact. The Court judgments formulate regulatory questions and propose answers  
about what constitutes a reasonable waiting time and what treatments should be available. By 
introducing the doctrine of proportionality to national policies, it becomes the authoritative 
institution to review and set the overall standards for how national measures fulfil such procedural 
criteria.- For a national barrier to free movement such as authorisation to be maintained, it must 
stand the proportionality test and provide evidence that it is justifiable (de Búrca 1993; Tridimas 
1999). Judicial politics contains the same logic of reasoning as later captured in the regulatory 
politics of the Commission. The justifiability of national obstacles must be proven, be necessary 
and suitable.  
Instead of focusing on the need to balance national healthcare supplies, the Court underlines that 
rules and regulation must be objective, non-discriminatory, and decisions must be based on 
objective assessments, formulated by experts who are both impartial and independent. In its detailed 
manner, the Court dissects the allocative mechanisms of the healthcare area, offers new venues to 
bypass the restrictions of national supplies and build up new redistributive cross-border routes.     
 
3. Political responses and the first regulatory proposal  
When the European Court of Justice issued its Decker and Kohll rulings, politicians reacted 
forcefully. The German Government, for example, initially spoke out very strongly against the 
Decker/Kohll judgements. The former German Minister of Health, Seehofer, was quick to argue 
that the rulings would undermine the German health system. He further held that the Court 
decisions were against the preferences of the member states and that the politicians should overturn 
the rulings through a Treaty amendment (Langer 1999, p. 54; Børsen, 7. May 1998; Politiken 9 
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June 1998). The former Minister found the Decker/Kohll case-law revolutionary and argued that if 
Germany adopted its premises, it would be a long-term threat to the sustainability of the German 
health system (Spiegel 17/98, Fokus from 4 May 1998; Schaaf 1999, p. 274; Eichenhofer 1999; 
Interview, Deutsche Verbindungsstelle, 18 September 2001).  
 
This initial outburst is in sharp contrast to the subsequent political response as nothing further 
happened. No treaty amendment. No formal legislative reactions. Meanwhile judicial integration 
proceeded. 
 
In 2004, the Commission made its first attempt to regulate. It proposed to integrate the healthcare 
area in the proposal for a Directive on services in the internal market.
9
 As a precise reproduction of 
the Court’s decisions, Article 23 of the new directive proposed 1) an internal market for non-
hospital care, where the patient has a right to seek treatment in another member state without prior 
authorisation and subsequently have the costs reimbursed by the competent national institution, and 
2) a right to hospitalisation in another member state, provided that the member state of affiliation 
offers the same treatment, and that authorisation has been granted beforehand. The health ministers, 
however, refused to have their policy area regulated as part of a general Directive on services, 
placed under the responsibility of DG Internal Market. Article 23 and thus the healthcare area was 
subsequently taken out of the service directive.
10
  
 
3.1 Conflicting interests in  healthcare regulation  
It seemed clear that European healthcare could not be regulated purely on the basis of internal 
market norms. However, the Commission argued that the judicial decisions called for political 
codification and more administrative transparency. In September 2006, DG Health (SANCO) 
embarked on a consultation procedure on health services.
11
 The Communication called for 
stakeholders to state their opinions on a set of questions related to the cross-border provision of 
                                                 
9
 COM (2004) 2, 5 March 2004. Proposal for a Directive of the European Parliament and of the Council on Services in 
the Internal Market. 
 
10
 For an analysis of the high political salience of the service directive, see Schmidt (2009), this issue. 
 
11
 The Communication is SEC (2006) 1195/4, 26 September 2006.  
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health services. This open hearing procedure produced no less than 280 responses from 
stakeholders, ranging from member states, regional governments, health care organisations, health 
care providers, insurers, the industry and even individual citizens. The many stakeholders’ 
contributions expressed a high level of split preferences (Martinsen 2007). The conflicts expressed 
in the many and varying contributions were, among others;  
 Some member states addressed the redistributive means of waiting lists and argued that by 
intervening in  the criteria for the use of waiting lists, waiting lists were challenged as means 
of planning capacity. Contained in the argument is that prior authorisation and waiting lists 
constitute fundamental rationing devices. These both concern the control of in- and outflow 
of patients.  
 Another concern regarding national allocative mechanisms was that patient mobility 
challenges the scope of the national healthcare packages and the quality thereof. If some 
member states for political, medical, economic and/or normative reasons have decided not to 
provide specific treatment, mobile patients may access such treatment in other member 
states. Member states may experience growing demand to refund such treatment provided in 
other member states. Examples of conflicts are cost-intensive cancer treatments offered 
publicly in some member states but considered experimental in others, abortion – legal in 
some member states, prohibited in others, eye operations, spa-treatments publicly provided 
in some member states but not in others etc. Although it is explicitly stated in Court 
decisions, as well as in the subsequent Commission’s proposal that the scope of cross-border 
treatment only covers what the patient is entitled to in his/her own member states, this 
concern has been continuously formulated, presumably due to the doubt that the Peerbooms 
ruling introduced, regarding access to what was considered experimental treatment in the 
Dutch healthcare coverage (see above).   
 Another line of conflict was the one emerging between new and old member states. In the 
debate on the challenges and impacts of patient mobility, it has been argued that the new 
member states may benefit from the development as they might attract patients from other 
member states by offering price competitive treatment. The new member states, on the other 
hand, fear that they might have a considerable inflow of foreign patients which challenge 
their ability to provide efficient and high quality healthcare for their own population. This 
point concerns intra-European allocative mechanisms. Also the conflict of equality was 
raised from a population perspective, pointing out that free movement will favour those who 
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can afford it. The European rules formulate that member states are only obliged to reimburse 
what the same treatment would have cost at home. Additional costs as well as cost of travel 
etc. must be paid by the patient him/herself. This favours those with private resources as 
well as patients from the majority of old member states where treatments are generally more 
expensive. 
 
The counter position to the opinions above which was expressed in some contributions was that 
patient mobility improves allocative efficiency, and that enhanced European competition could lead 
to cost reduction and contribute to financial reform. By integrating foreign supply, treatment can be 
offered at lower costs through an internal health market.     
 
Conflicts also concerned the intra-institutional ‘division of labour’. Internally in the Commission, it 
was not straightforward which DG should be in charge of formulating the health care mobility 
proposal (Interview, European Commission, 2007). Having had to leave patient mobility out of the 
Services Directive, it was, however, clear that internal market considerations should not be the 
primary ones in the directive proposal. On the basis of previous experiences, DG SANCO had a 
sufficiently persuasive platform to take charge of the formulation of the proposal, which it was 
required to formulate in cooperation with DG Employment, Social Affairs and Equal Opportunities 
and DG Internal Market. With SANCO in charge, it was communicated that the regulation 
primarily concerned supranational healthcare.  
 
DG SANCO announced that the proposal would be presented on the 19
th
 December 2007. However, 
surprisingly, on that same day the Commission decided to withdraw the proposal (EU observer 19
th
 
December 2007).  
 
Whereas it remains unclear what exactly triggered off the withdrawal, it is clear that many different 
actors and organisations worked behind the scene in the run-up to the presentation of the proposal. 
What is also clear is that split preferences were put forward to the Commission.  
 
First of all, the college of Commissioners appear to have disagreed strongly internally on the 
directive and its principles. Various cabinets intervened against the proposal just before it was 
presented. Some expressed concerns on the impact on national health systems (EU observer, 7
th
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February 2008). Others were concerned about  how the proposal would be received by the public, 
suggesting that it could cause protests similar to the ones on the service directive, which would be 
damaging during the process of ratification of the Lisbon Treaty.  
 
Secondly, European social NGOs accused the proposal of  not being sufficiently ambitious in the 
creation of a European system of healthcare regulation. The proposal would not effectively promote 
patient mobility and would not de facto ensure equal treatment, since patients themselves would 
have to reimburse the cost of travel and other expenses: 
 
“Why does the EU directive not take account of other issues which are in the general interest of everyone living in 
the EU, such as equal access to affordable high quality health services for all, including particularly vulnerable 
groups […] That would show that the commission understands the concept of collective solidarity, not only 
individual consumers’ right” (Fintan Farrel, president of Social Platform, quoted in EU Observer, 19 th December 
2007).      
 
Thirdly, and likely to have been the key factor, members of the Party of European Socialists (PES) 
group in the European Parliament urged the Commission to withdraw the proposal, arguing that it 
would have considerable negative consequences for national healthcare systems.  
 
The main theme was the role of ‘prior authorisation’ as a national means of control to foreign 
supplies of publicly financed treatments (Dagens Medicin, 1
st
 February 2008). A central argument 
from members of the PES group was that the proposal did not simply codify the legal 
interpretations by the ECJ, but furthered the integration process beyond the judicial developments 
(Politiken, 19
th
 January 2008); 
 
“The Commission moves one step further than the decisions from the European Court of Justice. It is highly 
problematic that prior authorisation is no longer required regarding the right to hospital treatment in another 
member state. That deprives the member states of the instrument of economic and capacity planning and runs the 
risk of financially draining the national healthcare systems, because the patients in this way can take money along 
outside their own member state” (Christel Schaldemose, PES member of the European Parliament, quoted in 
Dagens Medicin, 1
st
 February 2008. Author’s translation from Danish, emphasis added). 
 
PES members also strongly emphasised to the Commission that the timing was badly chosen while 
the Lisbon Treaty remained to be ratified in several member states (Politiken, 10
th
 January 2008). 
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The president of PES and member of the European Parliament, Poul Nyrup Rasmussen, wrote to all 
socialist commissioners, expressing PES’s concern, just before the Commission was to present its 
proposal (Politiken, 11
th
 January 2008). 
 
Within the line of arguments posed by PES members was the recurring one of concern about 
national sovereignty. That the national autonomy of the welfare state was severely challenged runs 
through the various arguments.  Several times it was emphasised that whereas integration up to the 
point brought by the ECJ needed clarification, further steps were unacceptable.  
 
3.2 The final proposal – attempt to manage conflicts  
The December 2007 attempt to achieve inter-institutional consensus to propose healthcare 
regulation failed, despite the careful preparations by the Commission. However, the then health 
commissioner Markos Kyprianou continued to argue the need to regulate in the field of cross border 
healthcare, given that the ECJ had already gone forward on institutionalisation. According to 
Kyprianou, the Commission had no other option but to regulate, being prompted by the ECJ rulings. 
Shielding behind a pro-active Court, the commissioner argued on the grounds of necessity;    
“I don’t think [we] have a choice […] It’s not an initiative of the commission to create any new right, [but] 
offering legal certainty” (Markos Kyprianou, Quoted in EU Observer 7th February 2008).  
 
On 2 July 2008, the Commission was finally successful in proposing the directive on patient 
mobility. The final directive proposal is not fundamentally different from the version set to be 
presented in December 2007.
12
 The amendments seem rather minor to the December version, 
however, the timing as well as the reactions from the members of the European Parliament were 
different indeed.  
 
In the proposal, the Commission tried to manage the conflicts and diverse interests previously 
expressed, by 1) referring to the ‘voice of law’, by 2) requiring evidence to justify eventual 
deviations from internal market principles and 3) by postponing salient conflicts to the 
implementation process.  
 
                                                 
12
 Proposal for a directive of the European Parliament and of the Council on safe, high quality and efficient cross-border 
healthcare (2007).  
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Regarding the ‘voice of law’, the final version maintains its heavy reliance on the decision making 
of the Court. The need to regulate is presented on basis of the Court’s interpretations. The reasoning 
in the proposal is therefore that whereas the individual cases are clear in themselves, there is a need 
to translate these individual rulings into a general framework and thereby improve theirgeneral 
clarity. The reasoning of the Court is ever present in the proposal and establishes the main 
justification as put forward in the background and preparatory work for proposing the directive. The 
proposal initiates with reference to the Court’s ruling and the judicial interpretations substantiate the 
need to regulate throughout the proposal with reasoning such as: ‘as the Court has held’, ‘as 
confirmed by the Court’, ‘as was recognised by the Court’, ‘as established by the Court’, ‘as already 
addressed by the Court’, ‘in the light of the case-law’, ‘in order to achieve a more general and 
effective application of principles developed by the Court’, etc. In this way the Commission tries to 
manage the potential conflict on competences by the rule of law, and it tries to downsize political 
conflict by presenting its aims through the more neutral voice of law. Member states are left with 
less choice when decision-making options are so clearly framed and reduced on the grounds of the 
Court’s previous interpretations.   
 
Regarding evidence, evidence constitutes the other frame of reasoning through which the 
Commission launches its proposal. In the first pages of the proposal’s background, various surveys, 
analyses and impact assessments are presented together with stakeholders’ contributions. In 
addition, a specific impact assessment on the proposal has been elaborated.
13
 
 
One of the main conflicts of interests in the proposal is whether prior authorisation is a justified 
barrier to the cross-border provision  of services. Addressing this conflict, the Commission 
constructs a delicate balance in order to manage it. As in the earlier draft, this proposal 
reemphasises that prior authorisation is not generally prohibited concerning hospital care – but if 
member states wish to maintain a system of authorisation, the justification for such necessity must 
be evidence-based.
14
 In this way, the Commission’s evidence requirement has strong resemblances 
to the Court’s principle of proportionality, according to which national measures must be 
                                                 
13
 SEC (2008) 2163 final. Commission staff working document - Accompanying document to the proposal for a 
Directive of the European Parliament and of the Council on the application of patients' rights in cross-border healthcare 
- Impact assessment. 
 
14
 Evidence-based justification regarding prior-authorisation is treated pp. 13-16 of the proposal, point 7.1-7.4. See also 
especially article 8.3.b, 8.4 and 8.5 of the proposal.  
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appropriate and necessary (Chalmers et al. 2006). Requiring proportional national measures is likely 
to be just as powerful an instrument in administrative politics as it is in judicial politics, since it puts 
the Commission in the position to review whether  national measures pass the test of suitability and 
the test of necessity.
15
  
 
Furthermore, conflicts are postponed to the implementation process of the proposal. When member 
states in the future are to notify the way they have implemented the directive, they have to inform 
the Commission whether they have maintained or introduced a prior authorisation procedure. It is in 
the post-legislative phase the Commission comes in as authoritative reviewer, in a position to 
demand evidence to justify such barrier to the free movement of services.  
 
National authorities must provide evidence that: 
“the consequent outflow of patients due to the implementation of the directive seriously undermines or is likely to 
seriously undermine the financial balance of the social security system and/or this outflow of patients seriously 
undermines, or is likely to seriously undermine the planning and rationalisation carried out in the hospital sector 
… (COM(2008) 414 final, p. 14).  
 
Also it is noticeable that the Commission is there first with evidence-reasoned arguments to the 
contrary. The Commission repeats that on the basis of its own impact assessments, it holds it 
unlikely that patient mobility will endanger the balances of national healthcare organisations. Thus 
the proposal represents evidence-based policy. Conflicts are put aside. Political positions  will not 
stand unless they are accompanied by evidence, put in a scientific way.  
 
Furthermore, with direct reference to the proportionality doctrine, the Commission emphasises that 
the possibility of introducing and justifying prior authorisation is severely limited by the case-law 
of the Court:  
“In such cases, and according to the relevant jurisprudence, the introduction of a prior authorisation scheme, 
which will limit the exercise of rights conferred upon the citizens directly by the EC Treaty, must be proportionate 
and justified by imperative reasons as those mentioned in the same case-law” (COM(2008) 414 final, ibid, 
emphasis added.).  
 
                                                 
15
 For the two tests when the ECJ carry out the doctrine of proportionality, see de Búrca 1993 and Tridimas 1999.  
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While the Commission admits that there may be exceptions to the general rule, it at the same time 
puts the ‘burden of proof’ for such exceptions on the member states. Furthermore, such proof shall 
be evidence based – and take previous case-law into account. The restrictions on the executive 
autonomy of the member states are thus high. 
 
Finally, as with the justification of prior authorisation, the severe conflict on where in practice to 
draw the line between hospital and non-hospital care is postponed to the implementation process. In 
several member states’ hearing contributions, opposition was expressed regarding what was 
considered a crude Court distinction between hospital and non-hospital care. In the proposal, the 
Commission addresses this conflict and aims to manage it by, eventually, allowing certain cost-
intensive or highly specialised forms of non-hospital care to be defined as hospital care, and thus 
allowing – if justified and proportionate – prior authorisation procedures.16 In order to manage the 
conflict between national and supranational preferences, the Commission allows for a list of special 
forms of non-hospital care to be adopted. The list will be developed  in the implementation phase 
under the administration of the Commission and supervised by member state representatives under 
the Commitology regulatory procedure.
17
 The Commission thus proposes a committee to deliberate 
compromise
18
 between salient conflicts of interests.  
 
With its regulatory proposal, the Commission attempts to bridge law and politics.  On the one hand, 
the existing Court rulings already constitute a legal framework; on the other hand the judicial 
process is not in itself a regulatory framework, since it has no mandate to set up the regulator. The 
Commission’s proposal contains several such regulators, including a European reference network to  
coordinate healthcare that requires particular expertise or resources, a network on health technology 
assessment to support cooperation between national authorities and a commitology committee to 
formulate the list for  special regulation of certain non-hospital treatments as described above.
19
 
Giving form and task to such future regulators means that the Commission proposes to take the 
interpretations of the Treaty’s article 49 ‘incomplete contracting’ out of the judicial space and into 
the regulatory sphere. In this way, it invites member states’ representatives to re-enter the scene.     
                                                 
16
 See point 7.3, page 15, point 30, page 27 and article 8.1.b and 8.2, p. 38 of the proposal.  
 
17
 See article 8.2 of the proposal.  
 
18
 See Joerges and Neyer (1997) for the deliberation ability of Commitology committees.  
 
19
 Respectively laid down in article 15, 17 and 8.2 of the proposal.  
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4. Concluding remarks 
Welfare regulation in the European Union continues to push forward, albeit in fragmented manner. 
Despite strong political preferences to maintain national competence, regulation finds its way into 
redistributive policies.  
 
The key findings of the analysis carried out are that regulatory competences may be extended 
through a powerful interplay between the European Court of Justice and the European Commission. 
Through the way that the regulatory proposal is reasoned on the basis of previous case-law, the 
Court becomes an institution which takes part in policy-shaping and frames policy options. The 
impact of Court rulings moves from ex-post interpretation of regulation in force into ex-ante 
validation of new regulatory activities. Despite the initial political response after the first rulings 
where politicians argued that the Court had to be reined in, this proposal is not braking or rolling 
back judicial decision-making, but instead codifying and in part progressing what the Court has laid 
down. The Court’s interpretations feed regulatory actions. The Court’s interpretations identify 
regulatory problems to be undertaken and lend regulatory formulations to the Commission. 
Proposing cross-border healthcare in the European polity, however, implies redistributive 
consequences and thus implications for the traditional allocative mechanisms of national welfare 
communities. Such implications raise severe and intense conflicts of interests which the 
Commission has to manage. It does so by at least three means: the voice of law, the requirement of 
evidence-based policy-making, and the postponement of central conflicts into the implementation 
phase.  
 
In the literature on the regulatory state, the Commission is often found to be a uniquely powerful 
agency (Majone 1996; Lodge 2008), in large part insulated from majoritarian democratic control 
(Mabbett and Schelke 2009, this issue). However, in the analysis conducted here, its powerfulness 
is conditioned by its ability to manage conflicts in the right way. The Commission as the European 
executive does not act on the basis of classic leadership, acting as a political entrepreneur presenting 
clear visions and directions. Instead the Commission presents its regulatory proposal as a sheer 
necessity, reasoned from a coherent set of landmark rulings by the Court, which leave no other 
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choice. Instead of being an entrepreneur, its strategy seems to act as a manager between strong 
positions and conflicts. As manager of conflicts, the Commission abstains from the ownership of 
the idea behind the proposal. Instead of putting forward a vision of leadership in granting rights to 
the citizens of Europe, the main justification for the proposal is that the rule of law has spoken. The 
more neutral voice of law is one prism to bend political conflicts. The other is evidence and 
justification. Here the Commission relies on the Court’s principle of proportionality and introduces 
a very powerful means to evaluate the suitability and appropriateness of national measures. The 
Commission itself will become the reviewer and evaluating regulator. The Court’s use of 
proportionality has been described as the most far reaching ground of review and the most potent 
weapon for the judge to use against a public policy (Tridimas 1999). The weight of an 
administrative proportionality test may prove very heavy, since few national measures are likely to 
pass the tests of necessity and suitability when they run up against  the fundamental liberties of the 
EU.  
 
The Commission has already developed a strong platform of evidence-reasoned arguments. It is 
there first with its reasoned opinions, which limit or set the way positions can be presented. Political 
assumptions, ideological or passionate viewpoints cannot do it in the long run. The main conflicts in 
the proposal are postponed to the implementation phase which is where evidence is set to rule. Only 
what is justified by imperative reasons, and documented in a scientific way will withstand the 
burden of proof. The implications for the input-legitimacy of the political process are clear. The 
scope to build up political arguments is reduced before negotiations even start, since the 
argumentative scene is framed a priori by law and evidence.   
 
The Commission as a conflict manager may be a powerful agency, but is not an independent one. 
Instead of independence, its room for manoeuvre is conditioned by its interlocutors and the 
likelihood of success is conditioned by its ability to present reasoned and justified proposals. Law 
and evidence constitute sword and shield in a process, where conflicts are as many as stakeholders. 
Whether the Commission has selected the right logic of reasoning and will be successful as conflict 
manager in the case of cross border healthcare remains to be seen in the negotiation processes 
ahead. However, one crucial factor which increases the likelihood of success is that an 
administrative, regulatory space is more tractable and controllable for politicians than the judicial 
space, which is further beyond the political realm. To re-regulate is the ‘lesser evil’ than 
 20 
uncontrollable judicial integration (Schmidt 2000; Schmidt 2004). For this reason, politicians may 
accept the invitation to re-enter the scene and re-regulate European healthcare.    
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